ArriVent BioPharma, Inc.
Nasdaq AVBP · Newtown Square, PA
Works in GI & liver · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
ArriVent BioPharma, Inc. is a clinical trial sponsor based in Newtown Square, PA, listed as Nasdaq AVBP. It has 5 active clinical trials with 1,790 planned participants, across 6 therapeutic areas.
Trial track record · since 2021
Financials · Nasdaq AVBP
Fundraising
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about ArriVent BioPharma, Inc
ArriVent BioPharma, Inc is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 1,790 planned participants, in GI & liver, Metabolic & endocrine, Oncology, Renal & urogenital and other areas. Since 2021 it has completed 0 trials and stopped 0 early.
ArriVent BioPharma, Inc is based in Newtown Square, PA and is listed as Nasdaq AVBP. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with ArriVent BioPharma, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-14.
Approve Suite is not affiliated with ArriVent BioPharma, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.